Skip to main content
Log in

Concern over QOL data in cancer drug reimbursement submissions

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Raymakers AJN, et al. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. Cancer : 23 Sep 2019. Available from: URL: http://doi.org/10.1002/cncr.32455

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Concern over QOL data in cancer drug reimbursement submissions. PharmacoEcon Outcomes News 838, 7 (2019). https://doi.org/10.1007/s40274-019-6252-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6252-4

Navigation